Rhythmocor capsules 48 pcs.

Rhythmocor is an original combined drug that has metabolic, membrane-stabilizing, antioxidant and antiarrhythmic effects.

The pronounced metabolic activity of Rhythmocor is due to the activation of redox enzymes, an increase in intracellular levels of ATP and creatine phosphate. These effects contribute to the optimization of the functioning of cell ion pumps. One of the mechanisms of action of Rhythmocor on cells under conditions of ischemia and hypoxia is the suppression of the intensity of free radical oxidation of proteins and POL. The use of the drug in conditions associated with the activation of free radical reactions is accompanied by a decrease in the permeability of cell membranes.

The drug exhibits antiarrhythmic effects and potentiates the clinical efficacy of antiarrhythmic agents.

The components of the drug are rapidly absorbed in the gastrointestinal tract. The maximum concentration in the blood is determined after 1-1.5 hours. The products of drug metabolism are excreted by the kidneys.

Comprehensive treatment: coronary artery disease; neurocirculatory dystonia; myocardial infarction; heart rhythm disturbances (atrial and ventricular extrasystolic arrhythmia), especially associated with a deficiency of magnesium and potassium ions; inflammatory diseases of the heart muscle (myocarditis); myocardiopathy; electrolyte metabolism disorders (correction of the level of magnesium and potassium ions); liver diseases of various etiologies, to increase the resistance of hepatocytes to various pathological influences (viral, inflammatory, intoxication); chronic fatigue syndrome.

Usually capsules are taken orally (with a small amount of water) 1-2 capsules 10-15 minutes before meals 3-4 times a day. When a therapeutic effect is achieved (usually after 5-7 days), the dose of the drug is reduced to 1 capsule 3 times a day. The method of application, doses of the drug and the duration of the course of treatment are set individually.

If it is necessary to quickly achieve a therapeutic effect, treatment begins with the use of the injectable form of the drug.

As an antiarrhythmic drug, Rhythmocor is used for atrial and ventricular extrasystolic arrhythmia, heart rhythm disturbances associated with hypomagnesemia and hypokalemia, for the prevention of paroxysmal atrial fibrillation (regardless of heart rate). Simultaneous use of the drug with cardiac glycosides reduces the risk of arrhythmogenic manifestations.

For chronic fatigue syndrome and to prevent migraine attacks, the drug is used 1 capsule 3 times a day for 3-6 months.

In children aged 3 to 6 years, the drug is used 1 capsule 2 times a day, in children 6-12 years – 1 capsule 3 times a day, in children over 12 years of age, the drug is prescribed as in adults.

Adults are prescribed 5-10 ml of Rhythmocor solution intravenously 1-2 times a day, previously diluted in 10 ml of 0.9% sodium chloride solution or 5% glucose solution. The drug is also used intravenously drip: 5-20 ml of the drug solution is diluted in 50-400 ml of 0.9% sodium chloride solution or 5% glucose solution. The course of treatment is 10-14 days.

For the treatment of “pirouette” tachycardia, the drug is administered intravenously, jet 10-20 ml of the drug solution, previously diluted in 10 ml of 0.9% sodium chloride solution or 5% glucose solution, after which they switch to intravenous drip infusion: 5-20 ml of the drug solution is diluted in 50-400 ml of 0.9% sodium chloride solution or 5% glucose solution.

Children 1-3 years old are prescribed the drug at the rate of 1-2 ml of the drug solution per 1 year of life, 1-2 times a day, diluted in 5-10 ml of 0.9% sodium chloride solution or 5% glucose solution;

children 3-6 years old – in a dose of 5 ml of the drug solution 1-2 times a day, diluted in 10 ml of 0.9% sodium chloride solution or 5% glucose solution;

children 6-12 years old – 5-10 ml of the drug solution 1-2 times a day, diluted in 10 ml of 0.9% sodium chloride solution or 5% glucose solution;

Children over 12 years of age are prescribed the drug in the same dose as adults.

Cardiogenic shock, systolic blood pressure in adults below 90 mm Hg, third-degree atrioventricular block, comatose state of unknown etiology, decompensated forms of diabetes mellitus, acute renal failure and chronic renal failure of degrees II-IV. Rhythmocor is contraindicated in hyperkalemia and hypermagnesemia.

The drug is well tolerated, side effects develop very rarely. In some cases, in individuals with increased individual sensitivity to the drug, dizziness may develop when using it, associated with the effect of the first dose. In these cases, the dose of the drug is reduced or canceled. After stopping the drug, side effects quickly disappear.

When prescribing Rhythmocor to patients with diabetes mellitus, the possibility of determining a falsely elevated blood glucose level when using the orthotoluidine method due to the presence of gluconic acid should be taken into account. During treatment with Rhythmocor, it is necessary to monitor the level of potassium and magnesium in the blood serum.

During pregnancy and breastfeeding, the use of the drug is possible if the expected benefit to the mother outweighs the potential risk to the fetus.

One capsule of the drug contains 0.03 XE.

One ampoule (5 ml or 10 ml) contains 0.008 or 0.016 XE, respectively.

When using Rhythmocor simultaneously with antiarrhythmic and hypotensive agents, their mutual enhancement of activity should be taken into account. When using the drug simultaneously with potassium-sparing diuretics and ACE inhibitors, it is necessary to monitor the level of potassium and magnesium in the blood serum. When used simultaneously with cardiac glycosides, the risk of their toxic effect on the heart is reduced.

When administered orally, cases of overdose have not been observed. Increased manifestations of hypersensitivity to the drug, development of hyperkalemia and hypermagnesemia are possible.

In a dry place, protected from light.